OR WAIT null SECS
CDMO looks to combat cancer at lower doses
MilliporeSigma, a contract development and manufacturing organization (CDMO) and life science business of Merck, has doubled its high-potent active pharmaceutical ingredient (HPAPI) production capacity with the expansion of its facility in Verona, WI. This new 65 million, 70,000 square-foot facility creates 50 new jobs.
HPAPIs provide cell-killing abilities at low doses, resulting in reduced side effects for patients. They are used in novel cancer therapies, including antibody drug conjugates (ADCs).
“There is an increasing demand for HPAPIs due to their effectiveness against cancer at lower doses and the trend towards more targeted therapeutics. Lower-doses of these therapies reduce the negative side effects for patients who are taking on this critical fight,” says Dirk Lange, head of life science services, life science business sector of Merck KGaA, Darmstadt, Germany. “Increasing capacity at our state-of-the-art facility in Verona, WI will allow us to meet the need for these key cancer treatment components.”